Abstract: Techniques described herein are directed to proxies configured to handle identity and access management for a web application. For instance, a first proxy receives requests to the application from a browser. The first proxy redirects the browser to an identity endpoint, which prompts the user to enter authentication credentials for the application. Upon successful authentication, the endpoint provides an access token for accessing web APIs to the first proxy. The first proxy provides the token to a second proxy, which stores the token. The second proxy receives anonymous API calls from the web application to the web APIs. When receiving an anonymous API call, the second proxy obtains the token and inserts it into an outgoing request to the API. Responsive to the API returning a message indicating that the token is invalid, the second proxy communicates with the first proxy to obtain a new token from the endpoint.

Abstract: Techniques described herein are directed to proxies configured to handle identity and access management for a web application. For instance, a first proxy receives requests to the application from a browser. The first proxy redirects the browser to an identity endpoint, which prompts the user to enter authentication credentials for the application. Upon successful authentication, the endpoint provides an access token for accessing web APIs to the first proxy. The first proxy provides the token to a second proxy, which stores the token. The second proxy receives anonymous API calls from the web application to the web APIs. When receiving an anonymous API call, the second proxy obtains the token and inserts it into an outgoing request to the API. Responsive to the API returning a message indicating that the token is invalid, the second proxy communicates with the first proxy to obtain a new token from the endpoint.

Abstract: Techniques described herein are directed to proxies configured to handle identity and access management for a web application. For instance, a second proxy receives requests to the application from a browser. The second proxy redirects the browser to an identity endpoint, which prompts the user to enter authentication credentials for the application. Upon successful authentication, the endpoint provides an access token for accessing web APIs to the second proxy. The second proxy provides the token to a first proxy, which stores the token. The first proxy receives anonymous API calls from the web application to the web APIs. When receiving an anonymous API call, the first proxy obtains the token and inserts it into an outgoing request to the API. Responsive to the API returning a message indicating that the token is invalid, the first proxy communicates with the second proxy to obtain a new token from the endpoint.

Abstract: Techniques described herein are directed to proxies configured to handle identity and access management for a web application. For instance, a first proxy receives requests to the application from a browser. The first proxy redirects the browser to an identity endpoint, which prompts the user to enter authentication credentials for the application. Upon successful authentication, the endpoint provides an access token for accessing web APIs to the first proxy. The first proxy provides the token to a second proxy, which stores the token. The second proxy receives anonymous API calls from the web application to the web APIs. When receiving an anonymous API call, the second proxy obtains the token and inserts it into an outgoing request to the API. Responsive to the API returning a message indicating that the token is invalid, the second proxy communicates with the first proxy to obtain a new token from the endpoint.

Abstract: The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Abstract: The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Abstract: The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

Abstract: A system includes a processor and machine readable instructions stored on a tangible machine readable medium and executable by the processor, for a computer program, configured to allow one or more accounts of an enterprise to access the computer program before the enterprise purchases and manages the computer program and to allow the computer program to implement, after the enterprise purchases and manages the computer program, one or more policies of the enterprise regarding use of the computer program without modifying the computer program.

Abstract: Disclosed herein is a microsphere for delivery to a target area in a patients body. The microsphere contains a mucin-affecting protease loaded therein and is adapted to release the mucin-affecting protease in a sustained manner when exposed to physiological conditions. Also disclosed are pharmaceutical compositions comprising the microspheres and methods of treatment involving the microspheres.

Abstract: Methods, systems, and computer program products are described herein for implementing a workflow development system that enables users to incorporate custom functionality within a workflow. During runtime execution of the workflow, the custom functionality (e.g., custom code) is executed in a sandboxed environment, thereby ensuring that the custom code consumes only a limited amount of computing resources (e.g., processing power, memory, storage, etc.) that may be shared with other processes. The foregoing may be achieved without requiring the user to be aware that a sandboxed environment is being utilized. Instead, the user simply needs to select and associate a custom function with a particular workflow step, and the workflow development system manages the interactions with the sandboxed environment without any further user involvement.

Abstract: A system includes a processor and machine readable instructions stored on a tangible machine readable medium and executable by the processor, for a computer program, configured to allow one or more accounts of an enterprise to access the computer program before the enterprise purchases and manages the computer program and to allow the computer program to implement, after the enterprise purchases and manages the computer program, one or more policies of the enterprise regarding use of the computer program without modifying the computer program.

Abstract: The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

Abstract: The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).